IgE is associated with exacerbations and lung function decline in COPD

Respiratory Research

Henrik Watz¹  Achim Müller²  Timotheus Speer³  Christian Herr⁴  Robert Bals⁴  Claus F. Vogelmeier⁵  Tobias Welte⁶  Rudolf A. Jörres⁷  Marek Lommatzsch⁸ 

[1] Airway Research Center North (ARCN), German Center for Lung Research (DZL), Pulmonary Research Institute at LungenClinic Grosshansdorf, Grosshansdorf, Germany;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany;Department of Internal Medicine IV, Nephrology, Saarland University Hospital, Homburg, Germany;Department of Internal Medicine V - Pulmonology, Allergology, Critical Care Medicine, Saarland University Medical Center, 66421, Homburg, Germany;German Center for Lung Research (DZL), Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Marburg, Germany;German Center for Lung Research (DZL), University of Hannover, Hannover, Germany;University of Munich, Munich, Germany;University of Rostock, Rostock, Germany;

关键词: COPD;    IgE;    Exacerbations;    Lung function decline;   

DOI  :  10.1186/s12931-021-01847-0

来源: Springer

【 摘 要 】

BackgroundBoth allergen-specific IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease characteristics in large COPD cohorts.MethodsCOSYCONET is a comprehensively characterized cohort of patients with COPD: total IgE and IgE specific to common aeroallergens were measured in serum of 2280 patients, and related to clinical characteristics of the patients. WISDOM is another large COPD population (2477 patients): this database contains the information whether total IgE in serum was elevated (≥ 100 IU/l) or normal in patients with COPD.ResultsBoth in COSYCONET and WISDOM, total IgE was elevated (≥ 100 IU/l) in > 30% of the patients, higher in men than in women, and higher in currently than in not currently smoking men. In COSYCONET, total IgE was elevated in patients with a history of asthma and/or allergies. Men with at least one exacerbation in the last 12 months (50.6% of all men in COSYCONET) had higher median total IgE (71.3 IU/l) than men without exacerbations (48.3 IU/l): this difference was also observed in the subgroups of not currently smoking men and of men without a history of asthma. Surprisingly, a history of exacerbations did not impact on total IgE in women with COPD. Patients in the highest tertiles of total IgE (> 91.5 IU/ml, adjusted OR: 1.62, 95% CI 1.12–2.34) or allergen-specific IgE (> 0.19 IU/ml, adjusted OR: 2.15, 95% CI 1.32–3.51) were at risk of lung function decline (adjusted by: age, gender, body mass index, initial lung function, smoking status, history of asthma, history of allergy).ConclusionThese data suggest that IgE may play a role in specific COPD subgroups. Clinical trials using antibodies targeting the IgE pathway (such as omalizumab), especially in men with recurrent exacerbations and elevated serum IgE, could elucidate potential therapeutic implications of our observations.

【 授权许可】

CC BY